Actionable Stock Market Trading Newswire. Built for Traders, by Traders. All news is property of their respective owners.
HomeNewsfeedsLexicon’s LX9211 Shows Significant And Consistent Benefits In The Treatment Of Painful Diabetic Neuropathy In Full Results From The Phase 2 RELIEF-DPN-1 Trial Presented At The 16th Annual Pain Therapeutics Summit
Lexicon’s LX9211 Shows Significant And Consistent Benefits In The Treatment Of Painful Diabetic Neuropathy In Full Results From The Phase 2 RELIEF-DPN-1 Trial Presented At The 16th Annual Pain Therapeutics Summit
Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6
Significant benefits demonstrated on burning pain and on pain interference with sleep
No evidence of withdrawal symptoms or
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX shares Outperform.
Preliminary estimated results for the second quarter include:
Average daily production between 65.0 and 65.5 thousand barrels of oil equivalent ("MBoe/d"), comprised of